 Product Service News
June 18, 2024
3D Systems Introduces EXT 800 Titan Pellet, Expanding Accessibility of Industrial Extrusion Platform ROCK HILL, S.C., June 18, 2024 Today, 3D Systems (NYSE:DDD) announced the latest addition to its industry-leading portfolio of EXT Titan Pellet systems the EXT 800 Titan Pellet. This new, compact pellet extrusion...
|
Clinical Study
June 18, 2024
In a remarkable stride towards global expansion, Intelligent Bio Solutions has initiated subject dosing and sampling for its FDA 510(k) Pharmacokinetic (PK) Study. This landmark study aims to assess the performance and effectiveness of their groundbreaking Intelligent Fingerprinting Drug Screening Technology. Undert...
|
Clinical Study
June 18, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersDay One, a leading biotechnology company focused on developing innovative therapies for cancer and rare diseases, has recently announced the expansion of i...
|
|
 Product Service News
June 18, 2024
()In a groundbreaking move, Treasure Global has recently unveiled their AI-driven ZCITY Super App, designed to integrate multiple essential features necessary for thriving in the digital era. By strategically partnering with industry leaders, the company is spearheading the charge in the artificial intelligence mark...
 Product Service News
June 18, 2024
Reborn Coffee Launches on Amazon, Expanding OMNI-Channel Strategy for E-Commerce GrowthReborn Coffee, a leading specialty coffee brand, has made its much-anticipated debut on Amazon, expanding its e-commerce presence and embracing an OMNI-channel strategy to drive revenue growth and capture a significant share of th...
|
|
Our most Popular Articles
|
Product Service News
January 8, 2024
Mereo BioPharma, a leading biopharmaceutical company with the chief aim to develop and commercialize innovative therapeutics, has recently provided an update on its formidable pipeline progress and corporate developments. Mereo is setting significant milestones with its strategic focus on rare diseases with the pote...
|
Business Update
December 13, 2023
Radius Recycling (RDUS), a subsidiary of Schnitzer Steel Industries, Inc., has unveiled its latest Fiscal Sustainability Report for 2023, aptly named Where Change Begins. The report, imbued with the company s plans for a profound ecological impact, provides a thorough look at the company s efforts in promoting ...
|
Business Update
June 3, 2024
Scholar Rock s SRK-181 Shows Promise in Advanced Solid Tumor Treatment: Phase 1 DRAGON Trial Results Unveiled CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a pioneering biopharmaceutical company dedicated to developing transformative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and othe...
|
|
|
Company News
|
Clinical Study
June 18, 2024
In a remarkable stride towards global expansion, Intelligent Bio Solutions has initiated subject dosing and sampling for its FDA 510(k) Pharmacokinetic (PK) Study. This landmark study aims to assess the performance and effectiveness of their groundbreaking Intelligent Fingerprinting Drug Screening Technology. Undert...
|
Clinical Study
June 18, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersDay One, a leading biotechnology company focused on developing innovative therapies for cancer and rare diseases, has recently announced the expansion of i...
|
Clinical Study
June 18, 2024
Erasca, a leading biopharmaceutical company, has recently commenced the SEACRAFT-2 pivotal Phase 3 trial to assess the efficacy and safety of a potential breakthrough treatment for NRAS-mutant melanoma. The combination therapy under investigation includes Naporafenib, a promising pan-RAF inhibitor, and Trametinib, w...
|
|
|
Company News
 Clinical Study
June 18, 2024
|
Company News
 Announcement
June 18, 2024
|
Company News
 Product Service News
June 18, 2024
|
More Company News
|
Clinical Study
June 18, 2024
|
Clinical Study
June 18, 2024
|
Announcement
June 18, 2024
|
Announcement
June 18, 2024
|
Business Update
June 18, 2024
|
Clinical Study
June 18, 2024
|
Clinical Study
June 18, 2024
|
Clinical Study
June 18, 2024
|
Clinical Study
June 18, 2024
|
Partnership
June 18, 2024
|
|
|
|
Related News
|
Management Announcement
|
Management Announcement
|
|
Stocks
|
Announcement
|
Clinical Study
|
Clinical Study
|
|
|
|
Business News
|
 Product Service News
()In a groundbreaking move, Treasure Global has recently unveiled their AI-driven ZCITY Super App, designed to integrate multiple essential features necessary for thriving in the digital era. By strategically partnering with industry leaders, the company is spearheading the charge in the artificial intelligence mark...
|
|
Product Service News
Reborn Coffee Launches on Amazon, Expanding OMNI-Channel Strategy for E-Commerce GrowthReborn Coffee, a leading specialty coffee brand, has made its much-anticipated debut on Amazon, expanding its e-commerce presence and embracing an OMNI-channel strategy to drive revenue growth and capture a significant share of th...
|
 Contract
Revolutionizing the Future of Transportation: How Airship AI s Technology is Transforming E-Commerce and LogisticsIn an era where the rapid pace of technological advancements is the norm, the logistics and e-commerce sectors stand at the forefront of innovation. Recently in a significant development, Airship AI has...
|
 Product Service News
Chijet Motor, a leading Chinese automotive company, recently announced its strategic move into the realm of automobile culture tourism. This ambitious venture comes as a result of an intention agreement signed between Chijet Motor s holding subsidiary, FAW JiLin Automobile Co., Ltd. (FAW JiLin), and the administrati...
|
 Product Service News
3D Systems Introduces EXT 800 Titan Pellet, Expanding Accessibility of Industrial Extrusion Platform ROCK HILL, S.C., June 18, 2024 Today, 3D Systems (NYSE:DDD) announced the latest addition to its industry-leading portfolio of EXT Titan Pellet systems the EXT 800 Titan Pellet. This new, compact pellet extrusion...
|
Our Most Popular Articles
|
 Product Service News
Mereo BioPharma, a leading biopharmaceutical company with the chief aim to develop and commercialize innovative therapeutics, has recently provided an update on its formidable pipeline progress and corporate developments. Mereo is setting significant milestones with its strategic focus on rare diseases with the pote...
|
 Business Update
Radius Recycling (RDUS), a subsidiary of Schnitzer Steel Industries, Inc., has unveiled its latest Fiscal Sustainability Report for 2023, aptly named Where Change Begins. The report, imbued with the company s plans for a profound ecological impact, provides a thorough look at the company s efforts in promoting ...
|
 Business Update
Scholar Rock s SRK-181 Shows Promise in Advanced Solid Tumor Treatment: Phase 1 DRAGON Trial Results Unveiled CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a pioneering biopharmaceutical company dedicated to developing transformative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and othe...
|
More News
|
 Clinical Study
In a remarkable stride towards global expansion, Intelligent Bio Solutions has initiated subject dosing and sampling for its FDA 510(k) Pharmacokinetic (PK) Study. This landmark study aims to assess the performance and effectiveness of their groundbreaking Intelligent Fingerprinting Drug Screening Technology. Undert...
|
 Clinical Study
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersDay One, a leading biotechnology company focused on developing innovative therapies for cancer and rare diseases, has recently announced the expansion of i...
|
 Clinical Study
Erasca, a leading biopharmaceutical company, has recently commenced the SEACRAFT-2 pivotal Phase 3 trial to assess the efficacy and safety of a potential breakthrough treatment for NRAS-mutant melanoma. The combination therapy under investigation includes Naporafenib, a promising pan-RAF inhibitor, and Trametinib, w...
|
 Clinical Study
Tonix Pharmaceuticals, a renowned pharmaceutical company dedicated to improving the lives of patients suffering from chronic pain conditions, recently presented significant data at the Annual Scientific Meeting of the American Headache Society (AHS). The data showcased a comparison between real-world treatment of mi...
|
|
Announcement
ProQR Therapeutics Advances RNA Editing Technology Platform with Promising Preclinical Data and Nominates New Board MemberProQR Therapeutics, a pioneering company in the field of transformative RNA therapies, announced significant developments at the RNA Editing Summit and the Annual General Meeting of Shareholders....
|
|
Product Service News
WalkMe, a leading digital adoption platform, has unveiled its latest innovation, WalkMe(X): The Premier Contextual AI Copilot Designed For The Enterprise. This cross-app copilot is uniquely suited for AI transformation and aims to democratize AI for every employee, ultimately driving unparalleled productivity within...
|
 Clinical Study
In recent announcements, FibroGen, Inc. has revealed significant advancements in the development of FG-3246, a potential innovative anti-CD46 antibody drug conjugate (ADC). These updates, ranging from positive interim results to the upcoming investor event, hold tremendous importance for FibroGen s position in the c...
|
|
Clinical Study
Assembly Biosciences, a biotechnology company focused on developing therapeutics for serious viral diseases, has recently announced the initiation of a Phase 1b clinical trial evaluating their next-generation capsid assembly modulator candidate, ABI-4334, for the treatment of chronic hepatitis B virus (HBV) infectio...
|
 Announcement
DENVER, May 20, 2024 In a significant move to expand the reach of its next-generation biometric identity platform, authID Nasdaq: AUID, a pioneering provider of biometric identity verification and authentication solutions, has announced an OEM partnership with Syntrove. This collaboration aims to integrate authID...
|
 Announcement
Kaltura s Continued Success and Competitive Positioning: A Closer Look at the Awards and Financial PerformanceIn today s rapidly evolving digital landscape, companies are constantly striving to innovate and adapt to meet the ever-changing needs of their customers. One company that has excelled in this regard is Kalt...
|
 Business Update
MIAMI Ryder System, Inc. (NYSE: R), a recognized leader in supply chain, dedicated transportation, and fleet management solutions, has earned the prestigious Supply & Demand Chain Executives Top Supply Chain Projects award for 2024. This accolade, appreciating projects designed to innovate and streamline supply ch...
|
 Clinical Study
CSIMarket.com is excited to announce the significant findings of Study 502, conducted by Intra-Cellular Therapies, which evaluated the efficacy of lumateperone as an adjunctive therapy in patients with Major Depressive Disorder (MDD). The study showcased statistically significant and clinically meaningful results,...
|
 Clinical Study
Rett Syndrome is a rare neurodevelopmental disorder primarily affecting females, characterized by a loss of acquired skills, severe cognitive impairment, motor dysfunction, and autonomic abnormalities. Taysha Gene Therapies is at the forefront of groundbreaking research in this field, developing a gene therapy called TSHA-102, which aims to address the root cause of Rett Syndrome by targeting the MECP2 gene mutation responsible for the condition. Recent clinical data from the ongoing REVEAL Phase 1/2 trials evaluating TSHA-102 have shown encouraging results across adult and pediatric patients, warranting further exploration and highlighting the potential of this novel therapeutic approach.Durable Improvements Across Clinical Domains:In their announcement, Taysha Gene Therapies reported significant and durable improvements across consistent clinical domains in both adult and pediatric patients who received TSHA-102 gene therapy. These improvements encompassed various aspects such as motor skills, communication and socialization abilities, autonomic function, seizure control, and an overall favorable safety profile. The positive outcomes observed in patients with different genetic mutation severities demonstrate the potential efficacy of TSHA-102 in addressing the diverse manifestations of Rett Syndrome.
|
 Clinical Study
BridgeBio Pharma, a company known for its prowess in genetic medicine, has reached a significant milestone in the quest for effective treatments for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Recently, the company announced that it has not only surpassed its interim analysis enrollment target for the Pha...
|
 Clinical Study
Altimmune, a leading clinical-stage biopharmaceutical company, has recently announced its plans to present clinical data on pemvidutide at the American Diabetes Association (ADA) 84th Scientific Sessions. This investigational drug is a GLP-1/glucagon dual receptor agonist designed for treating obesity and metabolic ...
|
|
Partnership
Zevra Therapeutics Partners with Orsini for Enhanced Distribution of OLPRUVA® (Sodium Phenylbutyrate) for Urea Cycle Disorders Celebration, Fla. and Elk Grove Village, Ill., June 18, 2024 - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), an innovative pharmaceutical company dedicated to developing and commercializing ...
|
|
|
|
|
